San Diego, USA-based Vividion Therapeutics has hired Jenna Goldberg to take the position of chief medical officer.
Vividion is a wholly-owned and independently operated subsidiary of German pharma major Bayer (BAYN: DE), acquired by the company in August 2021.
The firm is working on novel discovery technologies to unlock high value targets which have traditionally been regarded as undruggable, using precision therapeutics.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze